Advertisement
Screener

Elanco Animal Health Incorporated (ELAN) Costs and Expenses

2.8 / 5 stars · 68/120 Roast Me

Elanco Animal Health Incorporated Costs and Expenses

Elanco Animal Health Incorporated (ELAN) reported Costs and Expenses of $3.95 billion for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-25.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:CostsAndExpenses · last filed 2025-02-25

  • Elanco Animal Health Incorporated costs and expenses for the quarter ending 2024-12-31 was $1.07B, a 7.83% decline year-over-year.
  • Elanco Animal Health Incorporated costs and expenses for the quarter ending 2024-09-30 was $471.00M, a 78.24% decline year-over-year.
  • Elanco Animal Health Incorporated costs and expenses for the quarter ending 2024-06-30 was $1.22B, a 7.04% increase year-over-year.
  • Elanco Animal Health Incorporated costs and expenses for the quarter ending 2024-03-31 was $1.19B, a 3.83% increase year-over-year.
  • Elanco Animal Health Incorporated costs and expenses for fiscal 2024 was $3.95B, a 29.60% decline from fiscal 2023.
  • Elanco Animal Health Incorporated costs and expenses for fiscal 2023 was $5.61B, a 25.18% increase from fiscal 2022.
  • Elanco Animal Health Incorporated costs and expenses for fiscal 2022 was $4.48B, a 15.97% decline from fiscal 2021.
  • Elanco Animal Health Incorporated costs and expenses for fiscal 2021 was $5.33B, a 35.13% increase from fiscal 2020.
Period endCosts and Expenses 3 monthCosts and Expenses 3 month as first filedCosts and Expenses 6 monthCosts and Expenses 6 month as first filedCosts and Expenses 9 monthCosts and Expenses 9 month as first filedCosts and Expenses 12 monthCosts and Expenses 12 month as first filed
2024-12-31$1.07B
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25
$1.54B
derived: sum of 2 quarters · filed 2025-02-25
$2.76B
derived: sum of 3 quarters · filed 2025-02-25
$3.95B
10-K · filed 2025-02-25
2024-09-30$471.00M
10-Q · filed 2024-11-07
$1.69B
derived: sum of 2 quarters · filed 2024-11-07
$2.88B
10-Q · filed 2024-11-07
$4.04B
derived: sum of 4 quarters · filed 2025-02-25
2024-06-30$1.22B
10-Q · filed 2024-08-08
$2.41B
10-Q · filed 2024-08-08
$3.57B
derived: sum of 3 quarters · filed 2025-02-25
$5.74B
derived: sum of 4 quarters · filed 2025-02-25
2024-03-31$1.19B
10-Q · filed 2024-05-08
$2.35B
derived: sum of 2 quarters · filed 2025-02-25
$4.52B
derived: sum of 3 quarters · filed 2025-02-25
$5.66B
derived: sum of 4 quarters · filed 2025-02-25
2023-12-31$1.16B
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25
$3.33B
derived: sum of 2 quarters · filed 2025-02-25
$4.46B
derived: sum of 3 quarters · filed 2025-02-25
$5.61B
10-K · filed 2025-02-25
2023-09-30$2.17B
10-Q · filed 2024-11-07
$3.30B
derived: sum of 2 quarters · filed 2024-11-07
$4.45B
10-Q · filed 2024-11-07
$5.52B
derived: sum of 4 quarters · filed 2025-02-25
2023-06-30$1.14B
10-Q · filed 2024-08-08
$2.29B
10-Q · filed 2024-08-08
$3.36B
derived: sum of 3 quarters · filed 2025-02-25
$4.43B
derived: sum of 4 quarters · filed 2025-02-25
2023-03-31$1.15B
10-Q · filed 2024-05-08
$2.22B
derived: sum of 2 quarters · filed 2025-02-25
$3.29B
derived: sum of 3 quarters · filed 2025-02-25
$4.48B
derived: sum of 4 quarters · filed 2025-02-25
2022-12-31$1.07B
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25
$2.14B
derived: sum of 2 quarters · filed 2025-02-25
$3.33B
derived: sum of 3 quarters · filed 2025-02-25
$4.48B
10-K · filed 2025-02-25
2022-09-30$1.07B
10-Q · filed 2023-11-07
$2.26B
derived: sum of 2 quarters · filed 2023-11-07
$3.41B
10-Q · filed 2023-11-07
$3.42B
10-Q · filed 2022-11-08
$4.65B
derived: sum of 4 quarters · filed 2024-02-26
2022-06-30$1.19B
10-Q · filed 2023-08-07
$1.20B
10-Q · filed 2022-08-08
$2.34B
10-Q · filed 2023-08-07
$2.35B
10-Q · filed 2022-08-08
$3.58B
derived: sum of 3 quarters · filed 2024-02-26
$4.84B
derived: sum of 4 quarters · filed 2024-02-26
2022-03-31$1.15B
10-Q · filed 2023-05-09
$1.15B
10-Q · filed 2022-05-09
$2.39B
derived: sum of 2 quarters · filed 2024-02-26
$3.65B
derived: sum of 3 quarters · filed 2024-02-26
$5.16B
derived: sum of 4 quarters · filed 2024-02-26
2021-12-31$1.24B
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26
$2.50B
derived: sum of 2 quarters · filed 2024-02-26
$4.01B
derived: sum of 3 quarters · filed 2024-02-26
$5.33B
10-K · filed 2024-02-26
$5.33B
10-K · filed 2022-02-28
2021-09-30$1.26B
10-Q · filed 2022-11-08
$2.78B
derived: sum of 2 quarters · filed 2022-11-08
$4.10B
10-Q · filed 2022-11-08
$5.56B
derived: sum of 4 quarters · filed 2023-03-01
2021-06-30$1.51B
10-Q · filed 2022-08-08
$2.84B
10-Q · filed 2022-08-08
$4.30B
derived: sum of 3 quarters · filed 2023-03-01
$5.40B
derived: sum of 4 quarters · filed 2023-03-01
2021-03-31$1.32B
10-Q · filed 2022-05-09
$2.78B
derived: sum of 2 quarters · filed 2023-03-01
$3.88B
derived: sum of 3 quarters · filed 2023-03-01
$4.54B
derived: sum of 4 quarters · filed 2023-03-01
2020-12-31$1.46B
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01
$2.56B
derived: sum of 2 quarters · filed 2023-03-01
$3.22B
derived: sum of 3 quarters · filed 2023-03-01
$3.95B
10-K · filed 2023-03-01
$3.95B
10-K · filed 2021-03-01
2020-09-30$1.10B
10-Q · filed 2021-11-05
$1.10B
10-Q · filed 2020-11-06
$1.76B
derived: sum of 2 quarters · filed 2021-11-05
$2.49B
10-Q · filed 2021-11-05
$2.49B
10-Q · filed 2020-11-06
$3.28B
derived: sum of 4 quarters · filed 2022-02-28
2020-06-30$663.00M
10-Q · filed 2021-08-09
$663.40M
10-Q · filed 2020-07-30
$1.39B
10-Q · filed 2021-08-09
$1.39B
10-Q · filed 2020-07-30
$2.18B
derived: sum of 3 quarters · filed 2022-02-28
$2.96B
derived: sum of 4 quarters · filed 2022-02-28
2020-03-31$726.00M
10-Q · filed 2021-05-07
$725.50M
10-Q · filed 2020-05-07
$1.52B
derived: sum of 2 quarters · filed 2022-02-28
$2.30B
derived: sum of 3 quarters · filed 2022-02-28
$3.03B
derived: sum of 4 quarters · filed 2022-02-28
2019-12-31$791.50M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28
$1.58B
derived: sum of 2 quarters · filed 2022-02-28
$2.31B
derived: sum of 3 quarters · filed 2022-02-28
$2.99B
10-K · filed 2022-02-28
$2.99B
10-K · filed 2020-02-28
2019-09-30$783.80M
10-Q · filed 2020-11-06
$1.52B
derived: sum of 2 quarters · filed 2020-11-06
$2.20B
10-Q · filed 2020-11-06
$3.00B
derived: sum of 4 quarters · filed 2021-03-01
2019-06-30$731.40M
10-Q · filed 2020-07-30
$1.42B
10-Q · filed 2020-07-30
$2.22B
derived: sum of 3 quarters · filed 2021-03-01
$2.90B
derived: sum of 4 quarters · filed 2021-03-01
2019-03-31$686.30M
10-Q · filed 2020-05-07
$1.49B
derived: sum of 2 quarters · filed 2021-03-01
$2.17B
derived: sum of 3 quarters · filed 2021-03-01
$2.98B
derived: sum of 4 quarters · filed 2021-03-01
2018-12-31$801.50M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01
$1.48B
derived: sum of 2 quarters · filed 2021-03-01
$2.29B
derived: sum of 3 quarters · filed 2021-03-01
$2.95B
10-K · filed 2021-03-01
2018-09-30$682.30M
10-Q · filed 2019-11-08
$1.49B
derived: sum of 2 quarters · filed 2019-11-08
$2.15B
10-Q · filed 2019-11-08
$3.06B
derived: sum of 4 quarters · filed 2020-02-28
2018-06-30$810.20M
10-Q · filed 2019-08-13
$1.47B
10-Q · filed 2019-08-13
$2.38B
derived: sum of 3 quarters · filed 2020-02-28
$3.08B
derived: sum of 4 quarters · filed 2020-02-28
2018-03-31$658.70M
10-Q · filed 2019-05-14
$1.57B
derived: sum of 2 quarters · filed 2020-02-28
$2.27B
derived: sum of 3 quarters · filed 2020-02-28
2017-12-31$909.70M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28
$1.62B
derived: sum of 2 quarters · filed 2020-02-28
$3.12B
10-K · filed 2020-02-28
2017-09-30$706.20M
10-Q · filed 2018-11-08
$2.21B
10-Q · filed 2018-11-08
2016-12-31$2.94B
10-K · filed 2019-02-20

Similar stocks

Stock NameCountryMarket CapPE Ratio
MADRIGAL PHARMACEUTICALS, INC. (MDGL)United States$11.859B-38.17
BIOMARIN PHARMACEUTICAL INC (BMRN)United States$11.879B151.80
Axsome Therapeutics, Inc. (AXSM)United States$10.274B-66.82
CORCEPT THERAPEUTICS INC (CORT)United States$12.804B169.10
BridgeBio Pharma, Inc. (BBIO)United States$12.947B-20.72
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)United States$9.331B-42.28
Summit Therapeutics Inc. (SMMT)United States$13.071B-13.21
CYTOKINETICS INC (CYTK)United States$9.130B-11.86
Protagonist Therapeutics, Inc (PTGX)United States$8.883B95.52
TG THERAPEUTICS, INC. (TGTX)United States$8.805B19.05